Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...
Eli Lilly and Company (NYSE:LLY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
The Associated Press - Business News on MSN13d
Diabetes, obesity drugs fuel Eli Lilly’s 4Q profitEli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results